Year All20242023202220212020 May 31, 2024 Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies May 31, 2024 Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer May 29, 2024 Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) May 22, 2024 Invivyd Elects Two New Independent Members to its Board of Directors May 13, 2024 Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 9, 2024 Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights May 7, 2024 Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback May 2, 2024 Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights April 30, 2024 Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position April 15, 2024 Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
